SLC2A13 Activators
SLC2A13 Activators encompass a diverse array of chemical compounds that directly or indirectly catalyze the functional enhancement of the SLC2A13 protein, a glucose transporter. Forskolin, through the elevation of intracellular cAMP, activates protein kinase A, which may phosphorylate SLC2A13, enhancing its glucose transport capabilities by promoting its translocation or modulating its activity. Similarly, AICAR and Berberine engage the AMP-activated protein kinase pathway, leading to the cellular redistribution of SLC2A13, which augments glucose uptake. Insulin, by activating the PI3K/Akt signaling pathway, and Rosiglitazone, as a PPAR-gamma agonist, both contribute to the enhancement of SLC2A13 by facilitating its movement to the plasma membrane, thus potentiating glucose transport. Ionomycin, by increasing intracellular calcium, can activate kinases that may phosphorylate SLC2A13, leading to an increase in its transport activity, while Metformin, similar to AICAR and Berberine, activates AMPK, enhancing the protein's glucose transport function.
Further, compounds like Phloretin, although known to inhibit other glucose transporters, may indirectly increase the functional activity of SLC2A13 as a compensatory mechanism. Curcumin and Epicatechin gallate, by modulating insulin sensitivity and related pathways, support the trafficking of SLC2A13 to the plasma membrane, which in turn enhances glucose transport functionality. D-chiro-inositol, leveraging its role in insulin signal transduction, could potentiate SLC2A13's activity by mimicking insulin's effects, leading to increased plasma membrane localization of the transporter. Lastly, Alpha-lipoic acid, revered for its insulin-sensitizing properties, might facilitate the translocation of SLC2A13 to the plasma membrane, thus amplifying its glucose transport capacity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which can phosphorylate SLC2A13, leading to its functional activation by promoting its translocation or altering its transporter activity. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMP-activated protein kinase (AMPK). AMPK activation leads to the facilitation of glucose uptake by translocating SLC2A13 to the plasma membrane, thus enhancing the protein's glucose transport activity. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin activates the PI3K/Akt signaling pathway, which indirectly increases the translocation of SLC2A13 to the plasma membrane, enhancing its glucose transport activity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone, a PPAR-gamma agonist, enhances insulin sensitivity and indirectly increases the translocation and expression of SLC2A13 on the plasma membrane, thereby enhancing its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Elevated calcium can activate calcium-dependent protein kinases, which may phosphorylate SLC2A13, enhancing its glucose transport capacity. | ||||||
Metformin-d6, Hydrochloride | 1185166-01-1 | sc-218701 sc-218701A sc-218701B | 1 mg 5 mg 10 mg | $292.00 $822.00 $1540.00 | 1 | |
Metformin activates AMPK which can lead to the translocation of SLC2A13 to the plasma membrane and enhance its glucose transport function. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Berberine activates AMPK leading to increased glucose uptake through facilitation of SLC2A13 translocation to the plasma membrane. | ||||||
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $64.00 $255.00 | 13 | |
Phloretin inhibits SGLT1/2, potentially upregulating SLC2A13 activity as a compensatory mechanism for glucose transport, although primarily known for its effect on other glucose transporters. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin can modulate the AMPK pathway, which is known to result in the translocation of glucose transporters like SLC2A13 to the cell surface, thus enhancing its activity. | ||||||
α-Lipoic Acid | 1077-28-7 | sc-202032 sc-202032A sc-202032B sc-202032C sc-202032D | 5 g 10 g 250 g 500 g 1 kg | $69.00 $122.00 $212.00 $380.00 $716.00 | 3 | |
Alpha-lipoic acid improves insulin sensitivity and may stimulate the translocation of SLC2A13 to the plasma membrane, thereby enhancing its activity in glucose transport. | ||||||